Yttrium-90 Glass Microspheres Approved for Unresectable Hepatocellular Carcinoma

The FDA has approved yttrium-90 (Y-90) glass microspheres (TheraSphere™, Boston Scientific) for the treatment of patients with unresectable hepatocellular carcinoma (HCC). The most common type of primary liver cancer, HCC is often treated with surgery, liver transplantation, chemotherapy, or embolization. The radioactive Y-90 glass microspheres are delivered directly to the liver tumor through a catheter. The treatment, referred to as selective internal radiation therapy or embolization, minimiz...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.